IPO1 is overexpressed in solid cancers and hematological malignancies including diffuse large B‐cell lymphoma (DLBCL), chronic and acute myeloid leukemia, and multiple myeloma [11, 43, 46, 47], and associated with shorter overall survival for DLBCL patients [46]. Here, KPNB1 is linked to plasma cell myeloma.